← Back to Search

N/A

Citicoline for Cognitive Performance

N/A
Waitlist Available
Led By Kathleen Kelley, MD
Research Sponsored by Kirin Holdings Company, Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
male or female, 35-75 years of age
Be between 18 and 65 years old
Must not have
diagnosis of attention deficit hyperactive disorder (ADHD)
female who is pregnant, planning to be pregnant during the study period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-12 weeks

Summary

This trial tests if citicoline, a brain-boosting supplement, can improve attention in healthy men and women by increasing important brain chemicals. Citicoline is a naturally occurring compound that has shown beneficial effects on memory function and behavior in various populations with cognitive impairments.

Who is the study for?
This trial is for healthy men and women aged 35-75 who feel they have poor attention. They must score well on mental state and depression tests, not be color blind, or pregnant, and can't have ADHD or major illnesses that could interfere with the study.
What is being tested?
The trial is testing Citicoline (Cognizin®) against a placebo to see if it improves attention in healthy adults. Participants will take either the supplement or a placebo without knowing which one they're getting.
What are the potential side effects?
While Citicoline is generally considered safe, potential side effects may include headache, insomnia, diarrhea, low or high blood pressure, nausea, blurred vision, chest pains, and others.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 35 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with ADHD.
Select...
I am not pregnant and do not plan to become pregnant during the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Other study objectives
To assess the safety and tolerability of the TP in healthy participants: Reports of Adverse Events

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Cognizin®Active Control1 Intervention
Active ingredients: Citicoline
Group II: PlaceboPlacebo Group1 Intervention
Active ingredients: none

Find a Location

Who is running the clinical trial?

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.NETWORK
36 Previous Clinical Trials
2,012 Total Patients Enrolled
Kirin Holdings Company, LimitedLead Sponsor
2 Previous Clinical Trials
109 Total Patients Enrolled
Biofortis Clinical Research, Inc.Industry Sponsor
11 Previous Clinical Trials
950 Total Patients Enrolled
Daisuke Fujiwara, PHDStudy ChairKirin Holding Company Ltd. - Institute of Health Sciences
Kathleen Kelley, MDPrincipal InvestigatorBiofortis Clinical Research, Inc. Addison, Illinois, United States, 60101
6 Previous Clinical Trials
559 Total Patients Enrolled
~60 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top